

DAFTAR PUSTAKA

- Alhasan, A.H. *et al.*, 2016, 'Circulating microRNA signature for the diagnosis of very high-risk prostate cancer', *Proceedings of the National Academy of Sciences of the United States of America*, vol. 113(38), pp. 10655-60. Available at: <https://dx.doi.org/10.1073/pnas.1611596113>
- Bartel, D.P. *et al.*, 2009, 'MicroRNAs: target recognition and regulatory functions', *Cell*, vol. 136(2), pp. 215-33. Available at: <https://doi.org/10.1016/j.cell.2009.01.002>
- Bebelman, M.P., Smith, M.J., Pegtel, D.M. & Baglio, S.R., 2018, 'Biogenesis and function of extracellular vesicles in cancer', *Pharmacol Ther*, vol. 118, pp. 1-11. Available at: <https://doi.org/10.1016/j.pharmthera.2018.02.013>
- Bell, K.J., Del Mar, C., Wright, G., Dickinson, J. & Glasziou, P., 2015, 'Prevalence of incidental prostate cancer: A systematic review of autopsy studies', *Int J Cancer*, vol. 137(7), pp. 1749-1757. Available at: <https://doi.org/10.1002/ijc.29538>
- Benassi, B. *et al.*, 2012, 'MYC is activated by USP2a-mediated modulation of microRNAs in prostate cancer', *Cancer Discovery*, vol.2(3), pp. 236-247. Available at: <https://doi.org/10.1158/2159-8290.CD-11-0219>
- Bickley, L.S. & Szilagy, P.G., 2017, *Bates' Guide to Physical Examination and History Taking*, 12th edition, Wolters Kluwer. Philadelphia
- Boll, K. *et al.*, 2013, 'MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma', *Oncogene*, vol. 32(3), pp. 277-285. Available at: <https://doi.org/10.1038/onc.2012.55>
- Bonci, D. *et al.*, 2008, 'The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities', *Nat Med*, vol. 14(11), pp. 1271-1277. Available at: <https://doi.org/10.1038/nm.1880>
- Brozovic, A., Duran, G.E., Wang, Y.C., Francisco, E.B. & Sikic, B.I., 2015, 'The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells', *Mol Oncol*, vol. 9(8), pp. 1678-93. Available at:

<https://doi.org/10.1016/j.molonc.2015.04.015>

Bryant, R.J. *et al.*, 2012, 'Changes in circulating microRNA levels associated with prostate cancer', *British Journal of Cancer*, vol. 106(4), pp. 768–774. Available at: <https://doi.org/10.1073/pnas.0307323101>

Calin, G.A. *et al.*, 2004, 'Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers', *Proc Natl Acad Sci U S A*, vol. 101(9), pp. 2999–3004. Available at: <https://doi.org/10.1073/pnas.0307323101>

Calin, G.A. & Croce, C.M., 2006, 'MicroRNA signatures in human cancers', *Nat Rev Cancer*, vol. 6(11), pp. 857–866. Available at: <https://doi.org/10.1038/nrc1997>

Carlsson, J. *et al.*, 2011, 'A miRNA expression signature that separates between normal and malignant prostate tissues', *Cancer Cell International*, vol. 11, pp. 1–10. Available at: <https://dx.doi.org/10.1186%2F1475-2867-11-14>

Carter, H.B. *et al.*, 2012, 'Longitudinal Evaluation of Prostate-Specific Antigen Levels in Men With and Without Prostate Disease', *NIH Public Access*, vol. 267(16), pp. 2215–2220. Available at: <https://doi.org/10.1001/jama.1992.03480160073037>

Cassanova-Salas, I. *et al.*, 2014, 'Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatectomy', *Journal of Urology*, vol. 192(1), pp. 252–259. Available at: <https://doi.org/10.1016/j.juro.2014.01.107>

Chang, C.J. *et al.*, 2011, 'p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs', *Nature Cell Biology*, vol. 13(3), pp. 317–323. Available at: <https://doi.org/10.1038/ncb2173>

Chen, Z.H. *et al.*, 2012, 'A panel of five circulating microRNAs as potential biomarkers for prostate cancer', *Prostate*, vol. 72(13), pp. 1443–1452. Available at: <https://doi.org/10.1002/pros.22495>

Cho, W.C. *et al.*, 2007, 'OncomiRs: the discovery and progress of microRNAs in cancers', *Mol Cancer*, vol. 6(60), pp. 1–7. Available at: <https://doi.org/10.1186/1476-4598-6-60>

- Rainy, U. *et al.*, 1993, *Pembesaran Prostat Jinak : Beberapa Perkembangan Cara Pengobatan*. FKUI, Jakarta.
- Dunn, J.E. *et al.*, 1975, 'Cancer epidemiology in populations of the United States--with emphasis on Hawaii and California--and Japan', *Cancer Res*, vol. 35 (11), pp.3240-3245.
- Esquela-Kerscher, A. & Slack, F.J., 2006, 'Oncomirs - microRNAs with a role in cancer', *Nat Rev Cancer*, vol. 6(4), pp. 259-269. Available at: <https://doi.org/10.1038/nrc1840>
- Fan, L. *et al.*, 2012, 'Loss of E-cadherin promotes prostate cancer metastasis via upregulation of metastasis-associated gene 1 expression', *Oncology Letters*, vol. 4(6), pp. 1225-1233. Available at: <https://doi.org/10.3892/ol.2012.934>
- Feng, Y.H. & Tsao, C.J., 2016, 'Emerging role of microRNA-21 in cancer', *Biomedical Reports*, vol. 5(4), pp. 395-402. Available at: <https://doi.org/10.3892/br.2016.747>
- Fischer, N., Göke, F., Splittstößer, V., Lankat-Buttgereit, B., Müller, S.C. & Ellinger, J., 2012, 'Expression of programmed cell death protein 4 (PDCD4) and miR-21 in urothelial carcinoma', *Biochem Biophys Res Commun*, vol. 417(1), pp. 29-34. Available at: <https://doi.org/10.1016/j.bbrc.2011.11.035>
- Folini, M. *et al.*, 2010, 'miR-21: An oncomir on strike in prostate cancer', *Molecular Cancer*, vol. 9(12), pp. 2-7. Available at: <https://dx.doi.org/10.1186%2F1476-4598-9-12>
- Gandellini, P., Folini, M. & Zaffaroni, N., 2009, 'Towards the definition of prostate cancer-related microRNAs: where are we now?', *Trends in Molecular Medicine*, vol. 15(9), pp. 381-390. Available at: <https://doi.org/10.1016/j.molmed.2009.07.004>
- Ghorbanmehr, N., Gharbi, S., Korsching, E., Tavallaei, M., Einollahi, B. & Mowla, S.J., 2019, 'miR-21-5p, miR-141-3p, and miR-205-5p levels in urine-promising biomarkers for the identification of prostate and bladder cancer', *Prostate*, vol. 79(1), pp. 88-95. Available at: <https://doi.org/10.1002/pros.23714>
- Gordanpour, A. *et al.*, 2011, 'miR-221 Is down-regulated in TMPRSS2:ERG fusion-

- positive prostate cancer', *Anticancer Res*, vol. 31(2), pp. 403-410.
- Haas, G.P., Delongchamps, N., Brawley, O.W., Wang, C.Y. & de la Roza, G., 2008,' The worldwide epidemiology of prostate cancer: perspectives from autopsy studies', *Can J Urol*, vol.15(1), pp. 3866-71.
- Haj-Ahmad, T.A., Abdalla, M.A. & Haj-Ahmad,Y., 2014, 'Potential Urinary Protein Biomarker Candidates for the Accurate Detection of Prostate Cancer among Benign Prostatic Hyperplasia Patients', *J Cancer*, vol. 5(2), pp.103-114. Available at: <https://doi.org/10.7150/jca.6890>
- Hammond, S.M. *et al.*, 2006, 'MicroRNAs as oncogenes', *Curr Opin Genet Dev*, vol.16(1), pp. 4-9. Available at: <https://doi.org/10.1016/j.gde.2005.12.005>
- Heidenreich, A. *et al.*, 2011,' EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease', *European Urology*. vol. 59(1), pp. 61–71. Available at: <https://doi.org/10.1016/j.eururo.2010.10.039>
- Hessvik, N.P., Sandvig, K. & Llorente, A., 2013, 'Exosomal miRNAs as biomarkers for prostate cancer', *Frontiers in Genetics*, vol. 4(36), pp 1-9. Available at: <https://doi.org/10.3389/fgene.2013.00036>
- Hoffman, R.M., Gilliland, F.D., Adams-Cameron, M., Hunt, W.C. & Key, C.R., 2002, 'Prostate-specific antigen testing accuracy in community practice', *BMC Fam Pract*, vol. 3(19), pp. 1-8. Available at: <https://doi.org/10.1186/1471-2296-3-19>
- Howlader, N. *et al.*, 2011. 'SEER Cancer Statistics Review 1975-2009'. *National Cancer Institute*, pp.1992-2009.
- Hunter, M.P. *et al.*, 2008, 'Detection of microRNA expression in human peripheral blood microvesicles', *PLoS ONE*, 3(11),pp. 5-10. Available at: <https://doi.org/10.1371/journal.pone.0003694>.
- Isaacs, W.B. *et al.*, 1992, 'Expression of the Cellular Adhesion Molecule E-Cadherin Is Reduced or Absent in High-Grade Prostate Cancer', *Cancer Research*. 52(18).pp. 5104-9.
- Jalava, S.E. *et al.*, 2012, 'Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer', *Oncogene*, 31(41), pp.

4460–4471. Available at <http://doi: 10.1038/onc.2011.624>.

Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E. & Forman, D., 2011, ‘Global Cancer Statistic’, *Ca Cancer J Clin*, vol. 61(1), pp. 69–90. Available at: <https://doi.org/10.3322/caac.20107>

Jemal, A., Bray, F. & Ferlay, J., 2011, ‘Global Cancer Statistics’, 61(2), pp. 69–90. Available at: <https://doi: 10.3322/caac.20107>

Johnson, C.D. *et al.*, 2007, ‘The let-7 MicroRNA Represses Cell Proliferation Pathways in Human Cells’, (16), pp. 7713–7723. Available at : <https://doi: 10.1158/0008-5472.CAN-07-1083>.

Kirana, R. & Tjay, T.H., 2002, *Obat-Obat Penting: Khasiat, Penggunaan, dan Efek-Efek Sampingnya*. pp 222-365 Jakarta: Gramedia.

Karatas, O.F. *et al.*, 2014, ‘miR-1 and miR-133b are differentially expressed in patients with recurrent prostate cancer’, *PLoS ONE*, 9(6), pp. 1–7. doi: 10.1371/journal.pone.0098675.

Kasomva, K. *et al.*, 2017, ‘Abstract 5454: Serum circulating microRNAs as potential biomarkers for prostate cancer’, 3(1), pp. 5454–5454. Available at :<https://doi: 10.1158/1538-7445.am2017-5454>.

Kaya, E. & Feuer, D., 2004, ‘Prostate cancer : palliative care and pain relief,1 (1)’, pp. 311–315 Available at : <https://doi: 10.1038/sj.pcan.4500747>.

Kumarswamy, R., Volkmann, I. & Thum, T., 2011, ‘Regulation and function of miRNA-21 in health and disease’, *RNA Biology*. Taylor & Francis, 8(5), pp. 706–713 Available at: doi: 10.4161/rna.8.5.16154.

Le Sage, C., Nagel, R. & Agami, R., 2007, ‘Diverse ways to control p27Kip1 function: miRNAs come into play’, *Cell Cycle*, 6(22), pp. 2742–2749. Available at: <https://doi: 10.4161/cc.6.22.4900>.

Lewis, B.P. *et al.*, 2003, ‘Prediction of Mammalian MicroRNA Targets’, 115(7), pp:787-98. Available at : [https://doi.org/10.1016/s0092-8674\(03\)01018-3](https://doi.org/10.1016/s0092-8674(03)01018-3)

Li, T. *et al.*, 2012, ‘MiR-21 as an independent biochemical recurrence predictor and potential therapeutic target for prostate cancer’, *Journal of Urology*, 187(4), pp. 1466–1472. Available at: doi: 10.1016/j.juro.2011.11.082.

- Lodes, M.J. *et al.*, 2009, 'Detection of cancer with serum miRNAs on an oligonucleotide microarray', *PLoS ONE*, 4(7).pp. 3-10. Available at: doi: 10.1371/journal.pone.0006229.
- Lu, J. *et al.*, 2005, 'MicroRNA expression profiles classify human cancers', 435(June).pp 3-12. Available at: <https://doi.org/10.1038/nature03702>.
- Lynch, S.M. *et al.*, 2016, 'Regulation of miR-200c and miR-141 by Methylation in Prostate Cancer', *Prostate*. Available at: <https://doi.org/10.1002/pros.23201>.
- Martens-Uzunova, E.S. *et al.*, 2012, 'Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer', *Oncogene*, 31(8), pp. 978–991. Available at; <https://doi.org/10.1038/onc.2011.304>.
- Melbø-jørgensen, C.N. *et al.*, 2012, 'The expression of miR-21 in prostate cancer measured by in situ hybridization and its relevance as a diagnostic biomarker', pp. 1–40.
- Merrimen, J.L. *et al.*, 2009 'is a Significant Risk Factor for Prostatic Adenocarcinoma', *JURO*. American Urological Association, 182(2), pp. 485–490. Available at : <https://doi.org/10.1016/j.juro.2009.04.016>.
- Mitchell, P.S. *et al.*, 2008, 'Circulating microRNAs as stable blood-based markers for cancer detection', *Cancer Research Center*. 105(30), pp. 10513-8. Available at : <https://doi.org/10.1073/pnas.0804549105>
- Mochtar, C.A. *et al.*, 2015, 'Pedoman Penatalaksanaan Klinis Pembesaran Prostat Jinak (Benign Prostatic Hyperplasia / BPH)', *Indonesian Urological Association*, pp. 1–27.
- Moltzahn, F. *et al.*, 2011, 'Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients', *Cancer Research*, 71(2), pp. 550–560. Available at: <https://doi.org/10.1158/0008-5472.CAN-10-1229>.
- Moore, K.L., Dalley, F.A. & Agur, M.R.A., 2014, *Moore Clinically Oriented Anatomy*, 7th edition, Wolters Kluwer. Philadelphia
- Mortensen, M.M. *et al.*, 2014, 'High miR-449b expression in prostate cancer is associated with biochemical recurrence after radical prostatectomy', *BMC Cancer*, 14(1), pp. 1–7. Available at : <https://doi.org/10.1186/1471-2407-14-859>.

- Mottet, N. *et al.*, 2008, 'Highlights on Prostate Cancer from Urological and Oncological Congresses in 2007', 7, pp. 460–476. Available at: <https://doi:10.1016/j.eursup.2008.01.004>.
- Nakai, Y. & Nonomura, N., 2013, 'Inflammation and prostate carcinogenesis', *International Journal of Urology*, 20(2), pp. 150–160. Available at : <https://doi:10.1111/j.1442-2042.2012.03101.x>.
- Meyers, F.J. & Evans, C.P., 2005, 'Medical and surgical palliative care of patients with urological malignancies', *J Urol*, vol. 174(4), pp. 1177-82. Available at: <https://doi.org/10.1097/01.ju.0000173077.84274.01>
- Peng, X. *et al.*, 2011, 'Identification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT', *PLoS ONE*, 6(5).pp/10-14. Available at <https://doi:10.1371/journal.pone.0020341>.
- Petrova, Y.I., Schecterson, L. & Gumbiner, B.M., 2016, 'Roles for E-cadherin cell surface regulation in cancer', *Molecular biology of the cell*. 2016/08/31. The American Society for Cell Biology, 27(21), pp. 3233–3244. Available at: <https://doi:10.1091/mbc.E16-01-0058>.
- Pisitkun, T., Johnstone, R. & Knepper, M.A., 2006, 'Discovery of Urinary Biomarkers ', pp. 1760–1771. Available at: <https://doi:10.1074/mcp.R600004-MCP200>.
- Poliseno, L. *et al.*, 2010, 'A coding-independent function of gene and pseudogene mRNAs regulates tumour biology', *Nature*. Nature Publishing Group, 465(7301), pp. 1033–1038. Available at: <https://doi:10.1038/nature09144>.
- Poliseno, L. *et al.*, 2010, 'Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation', *Science Signaling*, 3(117).pp. 202-620 Available at: <https://doi:10.1126/scisignal.2000594>.
- Porkka, K.P. *et al.*, 2007, 'MicroRNA expression profiling in prostate cancer', *Cancer Research*, 67(13), pp. 6130–6135. Available at: <https://doi:10.1158/0008-5472.CAN-07-0533>.
- Porzycki, P. *et al.*, 2018, 'Combination of three miRNA (miR-141, miR-21, and

miR-375) as potential diagnostic tool for prostate cancer recognition', *International Urology and Nephrology*.25(3), pp55-98. Available at : <https://doi: 10.1007/s11255-018-1938-2>.

Purnomo, B.B., 2000, *Buku Kuliah Dasar-Dasar Urologi*, ed 3, CV Sagung Seto, Jakarta.

Putzke, A.P. *et al.*, 2011, 'Metastatic progression of prostate cancer and E-cadherin: Regulation by ZEB1 and Src family kinases', *American Journal of Pathology*.pp 15-76. Available at:[https:// doi: 10.1016/j.ajpath.2011.03.028](https://doi: 10.1016/j.ajpath.2011.03.028).

Rao, A.R., Motiwala, H.G. & Karim, O.M., 2007, 'The discovery of prostate-specific antigen From Prostate Tissue And Semen',62(5). pp. 5–10. Available at: [https:// doi: 10.1111/j.1464-410X.2007.07138.x](https://doi: 10.1111/j.1464-410X.2007.07138.x).

Reksoprodko, S. ,1995, 'Kumpulan Kuliah Ilmu Bedah', in. Jakarta: Binarupa Aksara.

Ribas, J. *et al.*, 2009, 'miR-21: An androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth', *Cancer Research*, 69(18), pp. 7165–7169. Available at : <https://doi: 10.1158/0008-5472.CAN-09-1448>.

Roehrborn, C.G., 2016, *Campbell-Walsh Urology*, 11th edition, Elsevier. Philadelphia

Rubin, M.A. *et al.*, 2001, 'E-cadherin expression in prostate cancer: A broad survey using high-density tissue microarray technology', *Human Pathology*. 32(7).pp.690-7: Available at: <https://doi: 10.1053/hupa.2001.25902>. Jul;

Rufino-Palomares, E.E. *et al.*, 2013, 'MicroRNAs as Oncogenes and Tumor Suppressors', *MicroRNAs in Medicine*, 30(2), pp. 223–243. Available at: <https://doi: 10.1002/9781118300312.ch14>.

Sabiston, D.C., 2012, 'Textbook Of Surgery: The Biological Basis Of Modern Surgical Practice 19th ed', United States : Philadelphia Elsevier Saunders.

Sachdeva, M. *et al.*, 2009, 'p53 represses c-Myc through induction of the tumor suppressor miR-145', *Proceedings of the National Academy of Sciences of the United States of America*, 106(9), pp. 3207–3212. Available at: <https://doi: 10.1073/pnas.0808042106>.

- Sanda, M.G. *et al.*, 2017, 'Association between combined TMPRSS2:ERG and PCA3 RNA urinary testing and detection of aggressive prostate cancer', *JAMA Oncology*.23(5), Available at : <https://doi.org/10.1001/jamaoncol.2017.0177>.
- Schaefer, A. *et al.*, 2009, 'Diagnostic and Prognostic Implications of MicroRNA Profiling in Prostate Carcinoma'. *International Journal of Cancer*, 126(5), pp.1166-1276. Available at: <http://dx.doi.org/10.1002/ijc.24827>.
- Scher, H.I. *et al.*, 2008, 'Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone : Recommendations of the Prostate Cancer Clinical Trials Working Group'. *Journal of Clinical Oncology*, 26(7), pp.1148-1159, Available at: <http://dx.doi.org/10.1200/JCO.2007.12.4487>.
- Selcuklu, S.D., Donoghue, M.T.A. & Spillane, C., 2009, 'miR-21 as a Key Regulator of Oncogenic Processes'. *Biochem Soc Trans*, 37, pp.918–925. Available at: <http://dx.doi.org/10.1042/BST0370918>.
- Selth, L.A. *et al.*, 2013, 'Circulating microRNAs Predict Biochemical Recurrence in Prostate Cancer Patients. *British Journal of Cancer*, 109(3), pp.641–650. Available at: <http://dx.doi.org/10.1038/bjc.2013.369>.
- Shen, M. & Abate-Shen, C., 2010, 'Molecular Genetics of Prostate Cancer: New Prospects for Old Challenges'. *Genes & Development*, 24, pp.1967-2000. Available at: <http://dx.doi.org/10.1101/gad.1965810>.
- Singh, S., Shukla, G.C. & Gupta, S., 2015, 'MicroRNA Regulating Glutathione S-Transferase P1 in Prostate Cancer'. *Current Pharmacology Reports*, 1(2), pp.79-88. Available at: <http://dx.doi.org/10.1007/s40495-014-0009-3>.
- Siomi, H. & Siomi, M.C., 2010, 'Posttranscriptional Regulation of MicroRNA Biogenesis in Animals'. *Molecular Cell*, 38(3), pp.323-332. Available at: <http://dx.doi.org/10.1016/j.molcel.2010.03.013>.
- Sjamsuhidajat, R. & Wim, de J., 1997, *Buku Ajar Ilmu Bedah*. Revisi. Penerbit ECG. Jakarta.
- Smith, B., Agarwal, P. & Bhowmick, N. A., 2004. 'MicroRNA Applications for Prostate, Ovarian and Breast Cancer in the Era of Precision Medicine'.

- Endocr Relat Cancer*, 24(5), pp.157-172. Available at: <http://dx.doi.org/10.1530/ERC-16-0525>.
- Sohel, M.M. *et al.*, 2016, 'Extracellular/Circulating MicroRNAs: Release Mechanisms, Functions and Challenges'. *Achievements in the Life Sciences*, 10(2), pp.175-186. Available at: <http://dx.doi.org/10.1016/j.als.2016.11.007>.
- Song, C. *et al.*, 2015, 'Expression Profile Analysis of microRNAs in Prostate Cancer by Next-Generation Sequencing'. *The Prostate*, 75(5). Pp.449-559. Available at: <http://dx.doi.org/10.1002/pros.22936>.
- Srivastava, A. *et al.*, 2013, 'MicroRNA Profiling in Prostate Cancer - The Diagnostic Potential of Urinary miR-205 and miR-214'. *PLoS ONE*, 8(10). Available at: <http://dx.doi.org/10.1371/journal.pone.0076994>.
- Stuopelyte, K. *et al.*, 2016, 'Detection of miRNAs in urine of prostate cancer patients', *Medicina (Kaunas)*. 52(2), pp.116-124. Available at: <http://dx.doi.org/10.1016/j.medici.2016.02.007>.
- Sun, C. *et al.*, 2008, 'TMPRSS2-ERG Fusion, a Common Genomic Alteration in Prostate Cancer Activates C-MYC and Abrogates Prostate Epithelial Differentiation', *Oncogene*, 27(40), pp.5348-5353. Available at: <http://dx.doi.org/10.1038/onc.2008.183>.
- Sun, T. *et al.*, 2009, 'The Role of Microrna-221 and Microrna-222 in Androgen-Independent Prostate Cancer Cell Lines', *Cancer Research*, 69(8), pp.3356-3363. Available at: <http://dx.doi.org/10.1158/0008-5472.CAN-08-4112>.
- Syah, S.M., 2019, 'Benign prostatic hyperplasia', *PennState Hershey Milton S. Hershey Medical Center*.
- Takeichi, M. *et al.*, 1993. 'Cadherins in Cancer: Implications for Invasion and Metastasis', *Current Opinion in Cell Biology*, 5(5), pp.806-811. Available at: [http://dx.doi.org/10.1016/0955-0674\(93\)90029-P](http://dx.doi.org/10.1016/0955-0674(93)90029-P).
- Taylor, B.S. *et al.*, 2010, 'Integrative Genomic Profiling of Human Prostate Cancer', *Cancer Cell*, 18(1), pp. 11-22. Available at: <http://dx.doi.org/10.1016/j.ccr.2010.05.026>.
- Truong, M. Yang, B. & Jarrard, D., 2012, 'Towards the Detection of Prostate Cancer in Urine: A Critical Analysis', *J Urol*, 189(2), pp.422-429. Available

- at: <http://dx.doi.org/10.1016/j.juro.2012.04.143>. Verdoodt, B. *et al.*, 2013. 'MicroRNA-205, a Novel Regulator of the Anti-Apoptotic Protein Bcl2, is Downregulated in Prostate Cancer', *International Journal of Oncology*, 43(1), pp.307-314. Available at: <http://dx.doi.org/10.3892/ijo.2013.1915>.
- Volinia, S. *et al.*, 2006. 'A microRNA Expression Signature of Human Solid Tumors Defines Cancer Gene Targets', *Proc Natl Acad Sci USA*, 103(7), pp.2257-2261, Available at: <https://doi.org/10.1073/pnas.0510565103>
- Wang, W. *et al.*, 2017, 'Down-regulation of E-cadherin Enhances Prostate Cancer Chemoresistance via Notch Signaling', *Chinese Journal of Cancer*. 36(1), Available at: <https://doi.org/10.1186/s40880-017-0203-x>.
- Wong, S.H.M. *et al.*, 2018, 'E-cadherin: Its Dysregulation in Carcinogenesis and Clinical Implications', *Critical Reviews in Oncology/Hematology*, 121, pp.11–22. Available at: <https://doi.org/10.1016/j.critrevonc.2017.11.010>.
- Woolf, S.H. *et al.*, 2001, 'The Accuracy And Effectiveness Of Routine Population Screening With Mammography , And Prenatal Ultrasound A Review Of Published Scientific Evidence ', *Cambridge University Press*, 17(3), pp. 275–304. Available at : <https://doi.org/10.1017/s0266462301106021>
- Wu, Z. *et al.*, 2013, 'Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer', *The Prostate*, 73(6), pp. 596–604. Available at: <https://doi.org/10.1002/pros.22600>.
- Yanaihara, N. *et al.*, 2006, 'Unique microRNA molecular profiles in lung cancer diagnosis and prognosis', *Cancer Cell*, 9(3), pp. 189–198. Available at: <https://doi.org/10.1016/j.ccr.2006.01.025>.
- Yang, J. & Weinberg, R.A., 2008, 'Review Epithelial-Mesenchymal Transition : At the Crossroads of Development and Tumor Metastasis', *Cancer Cell* , 14(6), pp. 818-29 Available at: <http://doi.org/10.1016/j.devcel.2008.05.009>.
- Yin, M. *et al.*, 2008, 'Prevalence of Incidental Prostate Cancer in the General Population : A Study of Healthy Organ Donors', 179(3), *The Journal of Urology*, pp. 892–895. Available at: <https://doi.org/10.1016/j.juro.2007.10.057>.
- Zeng, J. *et al.*, 2016, 'The clinical association of programmed cell death protein 4

(PDCD4) with solid tumors and its prognostic significance : a meta - analysis', *Chinese Journal of Cancer. BioMed Central*, 34(6), pp. 1–16. Available at : <http://doi: 10.1186/s40880-016-0158-3>.

Zennami, K. *et al.*, 2018, 'PDCD4 Is an Androgen-Repressed Tumor Suppressor that Regulates Prostate Cancer Growth and Castration Resistance', *Molecular Cancer Research*, 17(2), pp. 618–627. Availale at : <http://doi: 10.1158/1541-7786.mcr-18-0837>.

Zhang, B. *et al.*, 2007, 'microRNAs as Oncogenes and Tumor Suppressors', *Europe PMC*, 302(1), pp. 1–12. Available [http// doi: 10.1016/j.ydbio.2006.08.028](http://doi: 10.1016/j.ydbio.2006.08.028).